1,3,7-trimethyl-8-[4-(1H-tetrazol-1-yl)phenoxy]-3,7-dihydro-1H-purine-2,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,3,7-trimethyl-8-[4-(1H-tetrazol-1-yl)phenoxy]-3,7-dihydro-1H-purine-2,6-dione
• 英文别名: 1,3,7-trimethyl-8-[4-(tetrazol-1-yl)phenoxy]purine-2,6-dione
• 化学式: C₁₅H₁₄N₈O₃
• 分子量: 354.32
• InChiKey: SLTSAOGFNQOPON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE<br/>[FR] NOUVEAUX COMPOSÉS MODULANT LA GAMMA-SECRÉTASE ET LEUR UTILISATION DANS LE TRAITEMENT DES PATHOLOGIES ASSOCIÉES AUX ALPHA BÊTA, TELLES QUE LA MALADIE D'ALZHEIMER
  申请人：ASTRAZENECA AB

  公开号：WO2010132015A1

  公开（公告）日：2010-11-18

  The present invention relates to novel compounds of formulae (I) and (II) and therapeutically acceptable salts thereof, their pharmaceutical compositions processes for making them and their use in therapeutic methods for treatment and/or prevention of various diseases. In particular, the invention relates to compounds which interfere with γ-secretase and/or its substrate and hence modulate the formation of Aβ peptides.

  本发明涉及式(I)和(II)的新化合物及其治疗可接受的盐，它们的制药组合物的制备过程以及它们在治疗方法中的使用，用于治疗和/或预防各种疾病。具体来说，本发明涉及干扰γ-分泌酶及/或其底物并因此调节Aβ肽形成的化合物。
• Novel Compounds for A-Beta-Related Pathologies
  申请人：Lo-Alfredsson Yvonne

  公开号：US20100292210A1

  公开（公告）日：2010-11-18

  The present invention relates to novel compounds of formulae I and II and therapeutically acceptable salts thereof, their pharmaceutical compositions processes for making them and their use in therapeutic methods for treatment and/or prevention of various diseases. In particular, the invention relates to compounds which interfere with γ-secretase and/or its substrate and hence modulate the formation of Aβ peptides.

  本发明涉及公式I和II的新化合物及其治疗上可接受的盐，它们的制药组合物、制备方法以及它们在治疗和/或预防各种疾病的治疗方法中的用途。特别是，本发明涉及干扰γ-分泌酶及/或其底物的化合物，从而调节Aβ肽的形成。
• Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates
  申请人：Surolia Avadhesha

  公开号：US20100190832A1

  公开（公告）日：2010-07-29

  Transthyretin (TTR), a tetrameric thyroxine (T4) carrier protein, is associated with a variety of amyloid diseases. Derivative of biphenyl ethers (BPE), which are shown to interact with a high affinity to its T4 binding site thereby preventing its aggregation and fibrillogenesis. They prevent fibrillogenesis by stabilizing the tetrameric ground state of transthyretin. Two compounds (2-(5-mercapto-[1,3,4]oxadiazol-2-yl)-phenol and 2,3,6-trichloro-N-(4H-[1,2,4]triazol-3-yl) exhibit the ability to arrest TTR amyloidosis. The dissociation constants for the binding of BPEs and compound 11 and 12 to TTR correlate with their efficacies of inhibiting amyloidosis. They also have the ability to inhibit the elongation of intermediate fibrils as well as show nearly complete (>90%) disruption of the preformed fibrils. Biphenyl ethers and compounds 11 and 12 as very potent inhibitors of TTR fibrillization and inducible cytotoxicity.